Free Trial

Markets Remain on Vaccine Watch

GLOBAL

Markets remain on vaccine-watch after last week's interim results from Pfizer/BioNTech underpinned equities. Few vaccine candidates to look out for that had notable news this weekend:


  • AstraZeneca/Oxford: Speaking to The Sun over the weekend, the head of vaccine trial said "they are on track and "optimistic" to get the green light on the jab by Christmas" and that "the pioneering vaccine is on the cusp of demonstrating "efficacy"
  • Moderna: Expected to release first interim analysis in 'coming days' after completing enrolment on Oct22 and case accrual on Nov11.
  • Sanofi: Phase 2 results due early December, has confirmed vaccine would not need to be 'super-cooled' like the Pfizer/BioNTech candidate.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.